Cellosaurus MN-60 (CVCL_1421)

Cell line name MN-60
Synonyms MN 60; MN60
Accession CVCL_1421
Resource Identification Initiative To cite this cell line use: MN-60 (RRID:CVCL_1421)
Comments Part of: MD Anderson Cell Lines Project.
Doubling time: 25 hours (PubMed=6296550); ~48-60 hours (DSMZ).
Microsatellite instability: Instable (MSI-high) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Derived from sampling site: Peripheral blood.
Disease B acute lymphoblastic leukemia (NCIt: C8644)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ

Markers:
AmelogeninX,Y
CSF1PO11
D13S31711
D16S53911,12
D5S81812
D7S82010
TH019.3
TPOX8,9
vWA16,17
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=6296550; DOI=10.1016/0145-2126(82)90085-6
Roos G., Adams A., Giovanella B.C., Lundgren E., Nilsson K., Nordenson I., Sundstrom C.
Establishment and characterization of a human EBV-negative B cell line (MN 60).
Leuk. Res. 6:685-693(1982)

PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections DSMZ; ACC-138
Cell line databases/resources CLDB; cl3506
Cosmic-CLP; 908143
GDSC; 908143
LINCS_LDP; LCL-1010
Ontologies CLO; CLO_0007808
Biological sample resources BioSample; SAMN03473415
Chemistry resources ChEMBL-Cells; CHEMBL3308532
ChEMBL-Targets; CHEMBL2366070
Gene expression databases GEO; GSM1670120
Polymorphism and mutation databases Cosmic; 908143
Cosmic; 1012093